Johnson & Johnson reports phase 2 data showing nipocalimab reduced SLE disease activity
4th June 2026 Uncategorised 0
Late‑breaking EULAR results highlight sustained responses through week 52

More: Johnson & Johnson reports phase 2 data showing nipocalimab reduced SLE disease activity
Source: News
